Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Synta Will Sing A New Tune As Madrigal

This article was originally published in Scrip

Executive Summary

Synta Pharmaceuticals Corp. will sing a new tune as Madrigal Pharmaceuticals Inc. after an all-stock reverse merger that will give Madrigal shareholders a 64% stake in the combined company, which will focus on cardiovascular, metabolic and liver diseases instead of Synta's failed cancer programs.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register